New York based healthtech startup Junction has partnered with GRAIL to integrate the Galleri multi cancer early detection blood test into digital health platforms and healthcare organizations, using Junction’s diagnostic infrastructure to streamline ordering, workflows, and operational support across multiple states.
Glimpse:
Announced on April 9, 2026, the collaboration allows digital health companies and providers using Junction’s unified platform to easily order and manage the Galleri test directly within their clinical workflows. The Galleri test screens for signals from more than 50 cancer types, including many without standard screening options. This move aims to reduce administrative burdens and accelerate adoption of proactive multi cancer detection in real world care settings.
Junction, a New York based healthtech company specializing in diagnostic testing infrastructure, has joined forces with GRAIL, a California based biotech firm, to make the Galleri multi cancer early detection test more accessible. Through this partnership, organizations leveraging Junction’s platform can seamlessly incorporate the Galleri blood test into their existing patient care pathways. The infrastructure supports direct test ordering, efficient workflow management, coordination between patients and providers, and physician follow up services across multiple states.
The Galleri test is a single blood draw designed to detect a shared cancer signal from over 50 different cancer types, many of which currently lack recommended routine screening methods. By embedding this advanced diagnostic option into digital platforms, the collaboration addresses growing demand for proactive and preventive cancer care. Junction’s solution handles integrated test ordering, operational logistics, and data workflows, helping providers scale advanced testing without heavy administrative overhead.
This initiative comes as healthcare organizations seek reliable ways to operationalize cutting edge diagnostics at larger scales. The partnership simplifies the process for prescribing providers and platforms, enabling smoother integration into daily clinical practice while maintaining focus on patient outcomes. It reflects a broader industry shift toward infrastructure that supports scalable, efficient delivery of innovative tests like Galleri.
GRAIL views the collaboration as a key step to expand reach beyond traditional channels, particularly for cancers that contribute significantly to mortality but are not routinely screened. The combined capabilities are expected to help more providers offer the test confidently and efficiently, ultimately supporting earlier detection efforts nationwide.
“Single cancer screenings are an important tool for detection and diagnosis of five cancers in the U.S, but 70% of cancer deaths are caused by cancers without recommended screening tests. GRAIL is excited to collaborate with Junction to broaden access to the Galleri multi-cancer early detection test through a streamlined experience for healthcare organizations and prescribing providers. Junction’s infrastructure helps simplify the operational steps around offering Galleri, making it easier for providers to integrate the test into care delivery.”
By
HB Team
Related News
